恩华药业
(002262)
| 流通市值：191.51亿 | | | 总市值：219.51亿 |
| 流通股本：8.84亿 | | | 总股本：10.13亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,775,641,892.99 | 3,218,250,058.44 | 1,610,251,670.32 | 5,911,188,872.18 |
| 营业收入 | 4,775,641,892.99 | 3,218,250,058.44 | 1,610,251,670.32 | 5,911,188,872.18 |
| 二、营业总成本 | 3,469,272,034.8 | 2,364,783,063.73 | 1,251,661,776.48 | 4,768,546,017.03 |
| 营业成本 | 1,352,855,839.92 | 841,164,548.44 | 467,498,451.12 | 1,647,615,667.02 |
| 税金及附加 | 58,416,561.11 | 41,222,974.24 | 19,423,511 | 74,447,442.9 |
| 销售费用 | 1,385,346,244.87 | 1,038,749,060.61 | 534,735,583.98 | 2,114,321,377.81 |
| 管理费用 | 204,654,528.87 | 137,224,284.04 | 74,749,188.04 | 263,617,140.82 |
| 研发费用 | 474,361,166.7 | 312,070,622.47 | 156,792,536.9 | 685,535,013.44 |
| 财务费用 | -6,362,306.67 | -5,648,426.07 | -1,537,494.56 | -16,990,624.96 |
| 其中:利息费用 | 1,718,468.75 | 1,062,461.69 | 426,653.1 | 2,438,852.26 |
| 其中:利息收入 | 7,968,855.87 | 3,386,428.71 | 1,529,442.02 | 21,461,971.95 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 53,022,200.98 | 35,914,691.23 | 17,997,689.56 | 61,159,905.52 |
| 资产处置收益 | 120,254.16 | 102,555.04 | -5,229.56 | 165,788.21 |
| 资产减值损失(新) | -14,641,274.63 | -22,748,380.47 | -5,926,389.84 | -30,514,199.68 |
| 信用减值损失(新) | -24,184,258.57 | -17,113,709.47 | -15,464,077.35 | -9,170,427.82 |
| 其他收益 | 1,992,989.68 | 3,334,247.3 | 1,987,770.94 | 34,888,291.15 |
| 四、营业利润 | 1,322,679,769.81 | 852,956,398.34 | 357,179,657.59 | 1,199,172,212.53 |
| 加:营业外收入 | 452,466.2 | -42,922.77 | 115,237.35 | 3,955,982.36 |
| 减:营业外支出 | 17,553,262.48 | 7,094,227.51 | 1,571,092.11 | 30,045,843.76 |
| 五、利润总额 | 1,305,578,973.53 | 845,819,248.06 | 355,723,802.83 | 1,173,082,351.13 |
| 减:所得税费用 | 160,782,794.34 | 105,513,465.46 | 38,122,127.18 | 118,180,592.88 |
| 六、净利润 | 1,144,796,179.19 | 740,305,782.6 | 317,601,675.65 | 1,054,901,758.25 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,144,796,179.19 | 740,305,782.6 | 317,601,675.65 | 1,054,901,758.25 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,146,179,700.03 | 740,682,973.24 | 317,413,953.67 | 1,057,334,353.51 |
| 少数股东损益 | -1,383,520.84 | -377,190.64 | 187,721.98 | -2,432,595.26 |
| 扣除非经常损益后的净利润 | 1,159,496,550.51 | 745,987,159.61 | 318,264,144.09 | 1,057,820,598.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.14 | 0.73 | 0.31 | 1.05 |
| (二)稀释每股收益 | 1.14 | 0.73 | 0.31 | 1.05 |
| 八、其他综合收益 | - | - | - | -1,986,860.16 |
| 归属于母公司股东的其他综合收益 | - | - | - | -1,986,860.16 |
| 九、综合收益总额 | 1,144,796,179.19 | 740,305,782.6 | 317,601,675.65 | 1,052,914,898.09 |
| 归属于母公司股东的综合收益总额 | 1,146,179,700.03 | 740,682,973.24 | 317,413,953.67 | 1,055,347,493.35 |
| 归属于少数股东的综合收益总额 | -1,383,520.84 | -377,190.64 | 187,721.98 | -2,432,595.26 |
| 公告日期 | 2026-10-24 | 2026-08-18 | 2026-04-18 | 2026-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |